[Click eStock] "SK Biopharm, Growth Expected from a Long-Term Perspective"

[Asia Economy Reporter Hyungsoo Park] Samsung Securities on the 2nd presented a 'Buy' investment opinion and a target price of 100,000 KRW for SK Biopharm, which is listed on the KOSPI market, citing significant long-term growth potential.

Geunhee Seo, a researcher at Samsung Securities, stated, "The target price was calculated based on sales estimates in the US, Europe, and other regions for the pipeline, including the epilepsy treatment new drug cenobamate (product name XCOPRI®) and the sleep disorder treatment new drug solriamfetol (product name SUNOSI®)."

She added, "It is difficult to expect short-term performance improvement due to marketing costs for cenobamate and solriamfetol in the US and increased research and development (R&D) costs from expanded indications, but listing in major large insurance companies, European approval, and milestone receipts from Avel Therapeutics are positive factors for the stock price."

Researcher Seo forecasted, "Sales of solriamfetol in the US will be reflected in the full-year performance this year," and "Sales are expected to increase when solriamfetol is sold in Europe in the second half of the year," adding, "The point at which marketing effects become meaningful is expected to be in 2024."

This content was produced with the assistance of AI translation services.